RTTNews | Sep 24, 2020 06:25AM EDT

06:25 Thursday, September 24, 2020 (RTTNews.com) - Axsome Therapeutics, Inc. (AXSM) announced that AXS-07, the company's investigational medicine for the acute treatment of migraine, rapidly relieved and substantially reduced relapse of migraine pain, as compared to the potent active comparator rizatriptan, in the MOMENTUM Phase 3 trial. The company said AXS-07 showed faster and more durable relief of migraine pain as compared to rizatriptan. AXS-07 was safe and well tolerated in the trial.

AXS-07 is multi-mechanistic investigational medicine for the acute treatment of migraine, consisting of MoSEIC meloxicam and rizatriptan.

Read the original article on RTTNews ( https://www.rttnews.com/3131169/axsome-therapeutics-axs-07-shows-strong-efficacy-in-momentum-trial-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved